These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 20400170)

  • 21. Quaternary protein mimetics of gp41 elicit neutralizing antibodies against HIV fusion-active intermediate state.
    Sadler K; Zhang Y; Xu J; Yu Q; Tam JP
    Biopolymers; 2008; 90(3):320-9. PubMed ID: 18338371
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The broadly neutralizing HIV-1 IgG 2F5 elicits gp41-specific antibody-dependent cell cytotoxicity in a FcγRI-dependent manner.
    Tudor D; Bomsel M
    AIDS; 2011 Mar; 25(6):751-9. PubMed ID: 21330910
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mimotopes selected by biopanning with high-titer HIV-neutralizing antibodies in plasma from Chinese slow progressors.
    Zhang X; Han X; Dai D; Bao M; Zhang Z; Zhang M; Bice T; Zhao M; Cao Y; Shang H
    Braz J Infect Dis; 2012; 16(6):510-6. PubMed ID: 23141970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B'-infected patients.
    Charpentier C; Larrouy L; Visseaux B; Landman R; Levittas M; Storto A; Damond F; Yazdanpanah Y; Yeni P; Brun-Vézinet F; Descamps D
    J Antimicrob Chemother; 2012 Jun; 67(6):1459-61. PubMed ID: 22382470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression.
    van Gils MJ; Euler Z; Schweighardt B; Wrin T; Schuitemaker H
    AIDS; 2009 Nov; 23(18):2405-14. PubMed ID: 19770692
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AIDS/HIV. A boost for HIV vaccine design.
    Burton DR; Weiss RA
    Science; 2010 Aug; 329(5993):770-3. PubMed ID: 20705840
    [No Abstract]   [Full Text] [Related]  

  • 27. Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites.
    Watkins BA; Buge S; Aldrich K; Davis AE; Robinson J; Reitz MS; Robert-Guroff M
    J Virol; 1996 Dec; 70(12):8431-7. PubMed ID: 8970964
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New Connections: Cell-to-Cell HIV-1 Transmission, Resistance to Broadly Neutralizing Antibodies, and an Envelope Sorting Motif.
    Smith SA; Derdeyn CA
    J Virol; 2017 May; 91(9):. PubMed ID: 28250119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors.
    Rusert P; Kuster H; Joos B; Misselwitz B; Gujer C; Leemann C; Fischer M; Stiegler G; Katinger H; Olson WC; Weber R; Aceto L; Günthard HF; Trkola A
    J Virol; 2005 Jul; 79(13):8454-69. PubMed ID: 15956589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel ring structure in the gp41 trimer of human immunodeficiency virus type 1 that modulates sensitivity and resistance to broadly neutralizing antibodies.
    O'Rourke SM; Schweighardt B; Scott WG; Wrin T; Fonseca DP; Sinangil F; Berman PW
    J Virol; 2009 Aug; 83(15):7728-38. PubMed ID: 19474108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5).
    Joos B; Trkola A; Kuster H; Aceto L; Fischer M; Stiegler G; Armbruster C; Vcelar B; Katinger H; Günthard HF
    Antimicrob Agents Chemother; 2006 May; 50(5):1773-9. PubMed ID: 16641449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects.
    Sather DN; Stamatatos L
    Vaccine; 2010 May; 28 Suppl 2():B8-12. PubMed ID: 20510750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exposure to entry inhibitors alters HIV infectiousness and sensitivity to broadly neutralizing monoclonal antibodies.
    Kramer VG; Varsaneux O; Oliviera M; Colby-Germinario SP; Mesplède T; Wainberg MA
    J Acquir Immune Defic Syndr; 2014 Sep; 67(1):7-14. PubMed ID: 24872133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic barrier for attachment inhibitor BMS-626529 resistance in HIV-1 B and non-B subtypes.
    Fofana DB; Charpentier C; Maïga AI; Lambert-Niclot S; Sayon S; Désiré N; Simon A; Yazdanpanah Y; Katlama C; Descamps D; Calvez V; Marcelin AG; Soulié C
    J Antimicrob Chemother; 2015 Jan; 70(1):130-5. PubMed ID: 25270328
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative detection of HIV-1 particles using HIV-1 neutralizing antibody-conjugated beads.
    Kim BC; Ju MK; Dan-Chin-Yu A; Sommer P
    Anal Chem; 2009 Mar; 81(6):2388-93. PubMed ID: 19222190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of the Maraviroc-Resistant Mutation M434I in the C4 Region of HIV-1 gp120 on Sensitivity to Antibody-Mediated Neutralization.
    Boonchawalit S; Harada S; Shirai N; Gatanaga H; Oka S; Matsushita S; Yoshimura K
    Jpn J Infect Dis; 2016 May; 69(3):236-43. PubMed ID: 26166507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo patterns of resistance to the HIV attachment inhibitor BMS-488043.
    Zhou N; Nowicka-Sans B; Zhang S; Fan L; Fang J; Fang H; Gong YF; Eggers B; Langley DR; Wang T; Kadow J; Grasela D; Hanna GJ; Alexander L; Colonno R; Krystal M; Lin PF
    Antimicrob Agents Chemother; 2011 Feb; 55(2):729-37. PubMed ID: 21078948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Escape from humoral immunity is associated with treatment failure in HIV-1-infected patients receiving long-term antiretroviral therapy.
    Ouyang Y; Yin Q; Li W; Li Z; Kong D; Wu Y; Hong K; Xing H; Shao Y; Jiang S; Ying T; Ma L
    Sci Rep; 2017 Jul; 7(1):6222. PubMed ID: 28740221
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV gp120 H375 is unique to HIV-1 subtype CRF01_AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug.
    Schader SM; Colby-Germinario SP; Quashie PK; Oliveira M; Ibanescu RI; Moisi D; Mespléde T; Wainberg MA
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4257-67. PubMed ID: 22615295
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide.
    Ray N; Blackburn LA; Doms RW
    J Virol; 2009 Apr; 83(7):2989-95. PubMed ID: 19153234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.